Format

Send to

Choose Destination
Lancet. 1985 Mar 16;1(8429):602-4.

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

Abstract

Recombinant human interferon alfa-A (rIFN alpha A) had a dose-related suppressive effect on human T lymphotropic virus type III (HTLV-III) replication in vitro in normal peripheral-blood mononuclear cells (PBMC). Both single-dose and multiple-dose regimens were inhibitory. Such inhibitory concentrations (4-1024 units/ml) were not toxic to PBMC in culture, and were within the ranges achievable in blood after injection. These studies suggest that clinical trials of rIFN alpha A in early HTLV-III infection are warranted.

PMID:
2857946
DOI:
10.1016/s0140-6736(85)92144-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center